AnaptysBio Inc
Company Profile
Business description
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
Contact
10770 Wateridge Circle
Suite 210
San DiegoCA92121
USAT: +1 858 362-6295
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
117
Stocks News & Analysis
video
Do you qualify as 'rich'?
stocks
Megatrend Investing 2025 and beyond: ASX players to capitalise on the clean energy transition
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,660.30 | 31.90 | 0.37% |
| CAC 40 | 7,808.87 | 141.30 | -1.78% |
| DAX 40 | 21,296.26 | 435.79 | -2.01% |
| Dow JONES (US) | 43,917.06 | 627.60 | -1.41% |
| FTSE 100 | 8,536.57 | 137.39 | -1.58% |
| HKSE | 20,622.14 | 404.88 | 2.00% |
| NASDAQ | 19,184.49 | 442.96 | -2.26% |
| Nikkei 225 | 38,993.16 | 473.07 | 1.23% |
| NZX 50 Index | 12,905.04 | 94.72 | 0.74% |
| S&P 500 | 5,931.24 | 109.29 | -1.81% |
| S&P/ASX 200 | 8,402.40 | 23.00 | 0.27% |
| SSE Composite Index | 3,250.60 | 2.03 | -0.06% |